VJHemOnc Booth
VJHemOnc Boothadmin2020-05-07T23:50:16+00:00
VJHemOnc Boothadmin2020-05-07T23:50:16+00:00
Klaus Metzeler, MD, University of Leipzig, Leipzig, Germany, provides insight into the diagnosis and risk stratification of patients with myelodysplastic syndromes (MDS) and outlines some…
VJHemOnc is excited to share an exclusive case study exploring the current approach to the diagnosis and classification of follicular lymphoma.
Tune in to this week’s VJHemOnc podcast to learn more about current & emerging treatment options for acute & chronic GvHD, as well as the…
Jurjen Versluis, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, introduces a genomic classification system that can be used alongside measurable residual disease (MRD) to…
The 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) took place on April 12-14, 2024, in Budapest, Hungary. This event brought together experts from…
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses whether transplantation and chemotherapy are necessary for all patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia…
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study exploring cytogenetic and molecular associations with outcomes…
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement for the upcoming 10th World Congress on Controversies in Multiple Myeloma (COMy), which is…
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…